Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 1/20 | 0.48 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6248042 | 0.84 | TSHR (0.40) | TSHRMAPK1BCHEACHE | |
| SCHEMBL6249078 | 0.80 | TSHR (0.45) | TSHRMAPK1BCHEACHE | |
| SCHEMBL6245767 | 0.79 | TSHR (0.44) | ALOX5APTSHRMAPK1BCHEACHE | |
| SCHEMBL6244150 | 0.78 | BCHE (0.48) | TSHRMAPK1BCHEACHE | |
| SCHEMBL6244249 | 0.77 | BCHE (0.47) | TSHRMAPK1BCHEACHE | |
| SCHEMBL6244245 | 0.77 | BCHE (0.47) | TSHRMAPK1BCHEACHE | |
| SCHEMBL6500479 | 0.74 | ALOX5AP (0.40) | ALOX5APPTGER4 | |
| SCHEMBL737677 | 0.71 | MEN1 (0.63) | TSHRMAPK1 | |
| SCHEMBL7740526 | 0.70 | TSHR (0.60) | TSHRMAPK1 | |
| SCHEMBL28401609 | 0.69 | PLA2G4A (0.50) | ALOX5AP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6919331-B2 | Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-07-19 | — | — | US | disclosed |
| US-20030207868-A1 | Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents | BRISTOL-MYERS SQUIBB COMPANY | 2003-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207868-A1 | Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents | MAVS, ZC3HAV1, EIF2AK2 | ALOX5AP 3555/4885PTGER4 2443/4885TSHR 3860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.